Antibiotics for lung disease and cancer
Antonella Arcadu, Margherita S. Silani, Francesco Amati, Andrea Gramegna, Francesco Blasi, Stefano Aliberti
Source: Eur Respir Monogr 2022; 98: 299-305
Abstract
Lung cancer patients frequently present with respiratory tract infections. The presence of multidrug-resistant pathogens is associated with unfavourable outcomes, including the persistence of bacteraemia, metastatic infection and higher case-fatality rates. Antibiotics may increase the risk of cancer development, and affect cancer treatment efficacy and toxicity by inducing changes in the microbiota. Further research is needed to clarify the role of antibiotics in the dysregulation between the microbiota and the immune system, and is crucial for lung cancer prevention and treatment. Monitoring gut microbiota composition and administering protective commensal bacteria could potentially improve cancer treatment response and tolerability, leading to better oncological outcomes. Cite as: Arcadu A, Silani MS, Amati F, et al. Antibiotics for lung disease and cancer. In: Martínez-García MÁ, Gaga M, Fong KM, eds. Lung Diseases and Cancer (ERS Monograph). Sheffield, European Respiratory Society, 2022; pp. 299–305 [https://doi.org/10.1183/2312508X.10020821].
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Antonella Arcadu, Margherita S. Silani, Francesco Amati, Andrea Gramegna, Francesco Blasi, Stefano Aliberti. Antibiotics for lung disease and cancer. Eur Respir Monogr 2022; 98: 299-305
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|